Tardigrade protein stabilizes hemophilia treatment

Researchers from the University of Wyoming have used a protein from the tardigrade, a microscopic animal, to stabilize factor VIII, a vital clotting protein for treating hemophilia A, at room temperature for up to ten weeks. This discovery could reduce the need for a cold chain, which is essential for preserving many medications.

Tardigrade's survival secrets

The tardigrade, also known as the water bear, can survive extreme conditions such as complete desiccation, extreme cold, and even the vacuum of space. Its ability to endure these conditions is largely due to a family of proteins called CAHS, which help protect its cellular structures during stress.

CAHS D protein tested on factor VIII

Scientists isolated a specific CAHS protein, called CAHS D, from the tardigrade Hypsibius exemplaris. They tested its ability to protect factor VIII, a fragile human clotting protein essential for treating hemophilia A. This protein forms a hydrogel that slows the degradation of sensitive molecules, mimicking the effects of cold without refrigeration.

Factor VIII's usual fragility

Factor VIII is typically unstable at room temperature and degrades quickly, losing its effectiveness within days. The Wyoming team aimed to overcome this challenge by coating factor VIII with CAHS D and subjecting it to cycles of drying, rehydration, and heat. Their results showed that the protein remained stable for ten weeks without refrigeration.

Engineered protein variants

The researchers created two modified versions of CAHS D, called 2X Linker and one that alters the LR binding region. These modifications allowed them to adjust the hydrogel's density, tailoring the level of protection to different storage conditions. This flexibility could enhance the practicality of using the protein in various environments.

Broader implications for medicine

The discovery could significantly impact areas where a reliable cold chain is not available, such as underdeveloped regions, disaster zones, and even space missions. The study highlights how mechanisms from extremophiles like the tardigrade could be harnessed to improve medical treatments in challenging environments.

Tardigrade proteins in broader research

The use of tardigrade proteins is part of a growing field of research. In 2024, the same Wyoming team showed that CAHS D can stabilize biological materials in human cells. Meanwhile, other researchers, such as those at MIT and the University of Iowa, have used similar proteins to protect tissues during radiotherapy, showing the versatility of these biological tools.

Future steps for the research

While the study is a proof of concept, practical applications for patients are still in development. Researchers aim to refine the technology and ensure it meets medical standards before it can be used in real-world treatments. The goal is to use nature's resilience to overcome logistical barriers in healthcare.